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Abstract 
IMPORTANCE: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) is a major public 
health concern. Studies suggest that 1 in 3 infected with SARS-CoV-2 may develop PASC, 
including those without initial symptoms or with mild COVID-19 disease.1, 2 
OBJECTIVE: To evaluate the timing, duration, and health impacts of PASC reported by a 
large group of primarily non-hospitalized COVID-19 survivors. 
DESIGN, SETTING, AND PARTICIPANTS: A survey of 5,163 COVID-19 survivors 
reporting symptoms for more than 21 days following SARS-CoV-2 infection. 
Participants were recruited from Survivor Corps and other online COVID-19 survivor 
support groups. 
MAIN OUTCOMES AND MEASURES: Participants reported demographic information, as 
well as the timing, duration, health impacts, and other attributes of PASC. The temporal 
distribution of symptoms, including average time of onset and duration of symptoms were 
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determined, as well as the perceived distress and impact on ability to work. 
RESULTS: On average, participants reported 21.4 symptoms and the number of symptoms 
ranged from 1 to 93. The most common symptoms were fatigue (79.0%), headache (55.3%), 
shortness of breath (55.3%), difficulty concentrating (53.6%), cough (49.0%), changed sense 
of taste (44.9%), diarrhea (43.9%), and muscle or body aches (43.5%). The timing of 
symptom onset varied and was best described as happening in waves. The longest lasting 
symptoms on average for all participants (in days) were “frequently changing" symptoms 
(112.0), inability to exercise (106.5), fatigue (101.7), difficulty concentrating (101.1), memory 
problems (100.8), sadness (99.2), hormone imbalance (99.1), and shortness of breath (96.9). 
The symptoms that affected ability to work included the relapsing/remitting nature of illness 
(described by survivors as “changing symptoms”), inability to concentrate, fatigue, and 
memory problems, among others. Symptoms causing the greatest level of distress (on scale of 
1 “none” to 5 “a great deal”) were extreme pressure at the base of the head (4.4), syncope 
(4.3), sharp or sudden chest pain (4.2), brain pressure (4.2), headache (4.2), persistent chest 
pain or pressure (4.1), and bone pain in extremities (4.1). 
CONCLUSIONS AND RELEVANCE: PASC is an emerging public health priority 
characterized by a wide range of changing symptoms, which hinder survivors’ ability to work. 
PASC has not been fully characterized and the trajectory of symptoms and long-term 
outcomes are unknown. There is no treatment for PASC, and survivors report distress in 
addition to a host of ongoing symptoms. Capturing patient reports of symptoms through open-
ended inquiry is a critical first step in accurately and comprehensively characterizing PASC to 
ensure that medical treatments and management strategies best meet the needs of individual 





The long-term effects of infection with SARS-CoV-2 are poorly understood. This is 
particularly alarming given that over 118,000,000 persons have contracted SARS-CoV-2 since 
the virus emerged in late 2019.3 Recent studies suggest that nearly a third of individuals 
having had SARS-CoV-2 infection, including those who are initially asymptomatic, go on to 
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develop symptoms that appear to last for a yet undefined period of time.1 These COVID-19 
survivors report a wide range of long-lasting sequelae,4 some of which are ongoing nine 
months after infection.5 
To date most of the research involving SARS-CoV-2 and its consequences has involved 
the 10% of individuals with severe illness that required hospitalization,6–8 leaving a significant 
gap in our understanding of the health impacts of SARS-CoV-2 infection among the majority 
(90%) of persons who have been infected to date – those that did not require hospitalization. 
As data emerged, persons with persistent symptoms 21 or more days following infection have 
been labeled as "long-haulers," or those with 
Post-Acute Sequelae of SARS-CoV-2 (PASC). Not only is public awareness surrounding this 
topic low, but research concerning PASC is minimal.9 Here, we characterize PASC among a 
participant group composed primarily of non-hospitalized COVID-19 survivors (n=5,163) 





Data for this project were procured through an IRB-approved study and was made 
possible by a collaboration between the Indiana University School of Medicine and Survivor 
Corps. Survivor Corps is a COVID-19 grassroots organization and Facebook group dedicated 
to supporting COVID-19 survivors and scientific research of COVID-19. In August 2020, a 
REDCap survey was disseminated to Survivor Corps group members on Facebook and in 
other online COVID-19 groups. The survey was sent out again in November 2020 to collect 
more data. The purpose of the survey was to understand respondents’ experiences with the 
timing and duration of the COVID-19 symptoms and how they were impacted by these 
symptoms. 
To participate in the study, all respondents had to be 18 years or older and have been 
diagnosed with COVID-19 through a positive SARS-CoV-2 antigen or RT PCR test, 
physician diagnosis, self-diagnosis, or some other method (e.g., positive antibody test). The 
survey collected self-reported demographic information, an extensive medical history 
(including underlying conditions), and experiences with COVID-19 (including 
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hospitalization). In addition, the survey listed and asked questions about 101 distinct 
COVID-19 symptoms and gave respondents the option to report additional symptoms they 
had experienced that were not listed. The initial survey collected 5,875 responses. 
All survey data were manually reviewed and cleaned for analysis. While asymptomatic 
respondents could participate, only data from respondents who reported symptoms were 
included in the results. To focus on the experiences of people with PASC, the data analyzed 
were further limited to respondents who had experienced symptoms for longer than 21 days. 
The final dataset for analysis consisted of 5,163 participants. 
For each symptom, the percentage of participants reporting the symptom, average pain or 
discomfort associated with the symptom, average duration, and average time to symptom onset 
were calculated. Means were calculated for participants’ responses to a 5-point Likert scale 
from "Not at all" to "Very much" for questions about the pain and discomfort, work 
impairment, and social relationship impact caused by each symptom. Additionally, the 
percentage of participants that reported the symptom as ongoing and the percentage who 
reported the symptom as intermittent was calculated for each symptom. The ggplot R package 
was used to visualize the relationship between symptom discomfort and average duration, the 
distribution of the number of symptoms reported by each participant, and to create a table 
containing all symptom metrics calculated for this study. 
Results 
Survey demographics  
A total of 5,875 people responded to the survey. Of these, 5,163 reported persistent 
symptoms. Participants were predominantly White (81.3%), female (85.7%), never 
hospitalized for COVID-19 (89.3%), and received either a provider diagnosis or RT-PCR 
confirmed SARS-CoV-2 infection (77.1%). See Table 1 for more detail. 
Prevalence and duration of symptoms among participants with PASC  
PASC individuals reported an average of 21.4 symptoms with a range of 1 to 93 
symptoms occurring (Supplemental Figure 1). The prevalence of symptoms is reported in 
Figure 1, and a graph of combined average time to symptom onset and duration among 
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participants with PASC is reported in Figure 2. Of the 101 symptoms reported, the most 
prevalent symptoms included fatigue, headache, shortness of breath, difficulty concentrating, 
inability to exercise, cough, change in sense of taste, diarrhea, and muscle or body aches. 
Timing of symptom onset varied and was typically described as occurring in “waves”. 
Symptom duration ranged from 2 weeks to over 100 days, with changing symptoms being a 
prominent, long-lasting feature (Figure 2). The first wave (arrhythmia to burning calves) 
appeared to be heavily dominated by neurological and cardiovascular manifestations with some 
indicators of a strong immune response (enlarged and painful lymph nodes), followed by 
microvascular consequences in the second wave (Covid toes). The final wave suggested impact 
on endocrine (thyroid) function. At the time that they took the survey 98.0% of the respondents 
said they had symptoms that were unresolved, and 97.8% reported that at least one of their 
symptoms was intermittent, meaning it would temporarily resolve and then later return.  
Impact of symptoms on participants with PASC  
The calculations of average time to symptom onset; symptom duration; percentage of 
respondents who reported the symptom as intermittent or ongoing; and the average symptom 
impact in terms of pain and discomfort, work impairment, and social relationship are recorded 
in Table 2. Variables included percentage reporting a symptom; pain and discomfort of the 
symptom (e.g., distress); ability to work or socialize; symptom duration; percentage reporting 
ongoing symptoms; and percentage reporting symptoms as intermittent. Potential morbidity, 
especially inability to work, was assessed through symptom severity, duration, and perceived 
impact on ability to work (Figure 3). 
Symptoms perceived to have the most impact on ability to work included fatigue, personality 
change, a sensation of “brain pressure”, inability to sleep, inability to exercise, difficulty 
concentrating, memory problems, confusion, shortness of breath, and the relapsing/remitting 
nature of symptoms. 
 
Conclusions 
The current study provides much needed insight into the sequelae of acute SARS-CoV-
2 infection. These findings warrant additional discussion, investigation, and context within 
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the current knowledge of PASC. In reviewing our findings, we believe there are 4 key take-
away points that warrant further discussion. 
First, the fact that survey participants reported an average of 24.1 symptoms means that 
the average PASC patient experiences more long-lasting sequelae of COVID-19 than is 
currently captured by most research studies.10, 11 The study’s ability to detect a larger number 
of symptoms can be attributed to including a list of potential COVID-19 symptoms based on 
initial open-ended research of the range of COVID-19 sequelae conducted in July of 20204 and 
expanded through feedback on the survey design from Survivor Corps. Strengths of this study 
include reporting of symptoms among the 5,163 individuals who have and are continuing to 
experience symptoms up to a year after SARS-CoV-2 infection, (PASC survivors). 
Participants were able to describe their symptoms and health impact caused by these 
symptoms in detail, which provides additional richness and insight into the symptom sequelae. 
     A second insight was that PASC may affect more women than men since 85.7% of our 
PASC respondents were women. Although prior research has found that older adults are at 
greater risk of hospitalization than younger adults, in our participant group PASC impacted 
people in the middle years of life most frequently with 77.0% (n= 3,980) of our participants 
aged 35-64. We2 and others8, 12, 13 have shown that PASC occurs more frequently in women with 
an age distribution similar to this study. Our participants were also largely not hospitalized, 
indicating a less severe initial course. 77% of participants reported clinician diagnosis or 
confirmed RT PCR for SARS-CoV-2, with 5% reporting “other” and ~18% self-diagnosing. 
Those without confirmed diagnosis may have attributed SARS-CoV-2 infection with a 
confirmed antibody test that was available early in the pandemic or through the presence of 
COVID-specific symptoms such as loss of sense of smell. While there may be an inclination for 
researchers to exclude participants who do not have a positive RT PCR or antibody test from 
COVID-19 research, capturing the experiences of the earliest long haulers (before validated 
tests had become available) is essential for understanding the trajectory of PASC. 
Third, participants reported multiple symptoms that appear to occur in waves. This 
observation is consistent with other reports, including hospitalized individuals. The temporal 
nature of these symptoms may provide clues into underlying pathophysiology, which is 
currently unclear. Others describe PASC symptoms occurring in waves which may indicate an 
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evolving process guided by endothelial dysfunction, inflammation, oxidative stress, and 
hormonal imbalance.14,15 However, a causal relationship has not been established. These 
findings align with the team’s prior work in different data sets that observed medically 
documented symptoms in electronic health records longitudinally and established a temporal 
order and inclusion of only new symptoms at 0-11 and 60+days following a positive SARS-
CoV-2 PCR test. In this work we identified 5 symptom clusters in non-hospitalized PASC 
survivors, with dominant symptoms in those clusters all represented in the top quartile of 
symptoms reported here. Of note is the changing nature of symptoms, which appears to be a 
particularly distressing feature among PASC survivors. 
Finally, PASC appears to exert variable degrees of impact on individuals, but 
mechanistic insight is lacking. Most studies to date have focused on hospitalized patients; 
however, in our study most participants were never hospitalized, suggesting that PASC has 
profound effects, independent of COVID-19 severity. Factors that were reported to have the 
most impact on participants’ ability to work after developing PASC included the 
relapsing/remitting nature of symptoms, the long duration of many symptoms reported as 
unresolved, as well as fatigue and symptoms associated with altered cognition or memory 
impairment. Overall, reported symptoms varied with regards to duration and for their degree 
of distress, suggesting that a symptom of PASC can cause severe health impacts for some and 
milder impacts for others, making PASC an experience that is unique to the individual. 
Considering the great number and severity of health impacts caused by PASC, future research 
with PASC patients should endeavor to collect qualitative data, asking patients to report on the 
lasting impacts including their ability to work, maintain social relationships, their mental 
health, as well as basic everyday functioning. Analysis and fusion of biological and qualitative 
data are essential to ensure that health policy can be designed to meet PASC survivors' needs. 
Limitations 
The sequelae of acute SARS-CoV-2 infection are just beginning to be understood, and it 
is clear that PASC affects those who were never hospitalized for severe illness. More work is 
needed to corroborate our findings and to document the temporal nature of symptoms of 
PASC. Further research is needed to determine non-modifiable risk factors associated with 
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increased risk of acquiring PASC, as well as aberrant innate and adaptive immune responses 





Thank you to Survivor Corps for mobilizing many thousands of COVID-19 survivors to 
participate in research to find a cure for COVID-19, and for being the epicenter of hope for so 
many. We would like to express our deep gratitude to the thousands of long haulers who spent 
many hours taking this survey while suffering from the impacts of PASC. The answers we need 
to cure PASC will come from listening and learning from those who suffer from the disease. 
 
We would also like to thank the Precision Health Initiative at Indiana University for their support 
on this project. 
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Table and Figure Legends 
Table 1. Participant demographics. Table showing distribution of participants based on race 
and ethnicity, gender, age, mode of determining SARS-CoV-2 infection, and hospitalization 
status.  
Table 2: COVID-19 symptoms and their health impacts. Health impact variables include: 
percentage of participants reporting symptoms, pain and discomfort (e.g. level of distress), 
ability to work, social impairment, symptom duration, percentage reporting symptoms as 
ongoing, and percentage reporting symptoms as intermittent. 
 
Figure 1: Percentage of respondents reporting each COVID-19 symptom. Graph showing 
percentage of participants (x-axis) who experienced a given symptom (y-axis). 
 
Figure 2. Average symptom onset and duration. Graph plotting the average time of 
symptom onset (in days after initial infection date) with average symptom duration. *Duration 
measures length of time the symptom was present and does not indicate resolution of the 
symptom. Participants noted these symptoms were ongoing at the time they completed the 
survey. 
 
Figure 3. Impact of level of distress and duration of symptoms on ability to work 
among PASC survivors. Graph showing the effect of duration of symptoms (x-axis) and 
level of distress (y-axis) on ability to work. Darker shades indicate greater impact on 
ability to work. 
 
Supplemental Figure 1. Distribution of the number of symptoms reported by participants. 
Graph visualizing the distribution of the number of symptoms reported by survey participants. 
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Table 1 Participant Demographics 
 
CHARACTERISTIC PARTICIPANTS (n=5163), No. (%) 
Race and Ethnicity:  
White 4198 (81.3) 
Hispanic or Latinx 330 (6.4) 
Multiracial 159 (3.1) 
Asian/Pacific Islander 114 (2.2) 
Black 111 (2.2) 
Hispanic or Latinx, White 89 (1.7) 
Black 41 (0.8) 
American Indian 35 (0.7) 
Hispanic or Latinx, 
Multiracial 
27 (0.5) 
Other 22 (0.4) 
Middle Eastern 19 (0.4) 
Hispanic or Latinx, American 
Indian 
7 (0.1) 
Hispanic or Latinx, Black 6 (0.1) 
Hispanic or Latinx, Other 3 (0.1) 




Female 4422 (85.7) 
Male 714 (13.8) 
Non-binary/non-conforming 15 (0.3) 
Unknown 10 (0.2) 
Transgender 2 (0.0) 
Age:  
18-24 118 (2.2) 
25-34 593 (11.5) 
35-44 1298 (25.1) 
45-54 1560 (30.2) 
55-64 1122 (21.7) 
65-74 428 (8.3) 
75-84 40 (0.8) 
85+ 4 (0.1) 
COVID-19 Diagnosis:  
Positive COVID-19 test 2644 (51.2) 
Diagnosis from doctor 1337 (25.9) 
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Self-diagnosed based on        
symptoms 
918 (17.8) 
Other 264 (5.1) 
Hospitalized:  
No 4918 (83.9) 
Yes 876 (15.5) 
NA 38 (0.6) 
 
  
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 27, 2021. ; https://doi.org/10.1101/2021.03.22.21254026doi: medRxiv preprint 




































Fatigue 4077 78.97 8.28 101.70 3.77 3.79 3.68 83.25 53.74 









2766 53.57 17.05 101.11 3.14 3.66 3.18 83.41 69.99 
Inability to 
exercise or be 
active 
2559 49.56 10.17 106.51 3.84 3.48 3.60 84.25 32.00 
Cough 2532 49.04 6.93 66.58 3.48 2.46 2.39 52.41 57.23 
Changed sense 
of taste 
2318 44.90 10.61 59.32 2.50 1.32 1.63 53.71 31.58 
Diarrhea 2268 43.93 13.00 51.73 3.50 2.49 2.39 44.22 63.62 
Muscle or body 
aches 2246 43.50 9.97 82.03 4.05 3.12 2.98 64.07 61.62 
Difficulty 
sleeping 
2159 41.82 17.36 95.81 3.59 3.35 3.16 80.45 50.58 
Memory 
problems 
2069 40.07 24.77 100.83 3.00 3.55 3.10 86.52 63.80 
Heart 
palpitations 
2038 39.47 24.61 86.23 3.51 2.90 2.74 76.55 84.69 
Partial or 
complete loss 
of sense of 
smell 
2036 39.43 8.38 58.23 2.50 1.47 1.71 48.33 22.94 
Dizziness 1943 37.63 21.50 79.86 3.53 3.14 2.92 68.76 82.86 
Fever or chills 1938 37.54 5.33 42.22 3.68 2.60 2.47 27.19 57.28 
Partial or 
complete loss 
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of sense of 
taste 
Bone aches in 
extremities 
1804 34.94 16.64 79.27 4.12 2.97 2.88 73.61 69.90 
Abdominal 
pain 1770 34.28 15.05 57.32 3.77 2.47 2.56 61.07 80.51 
Anxiety 1764 34.17 17.68 92.70 3.60 3.15 3.39 88.72 83.84 




1723 33.37 14.60 89.38 4.12 3.30 3.15 66.69 67.38 
Confusion 1712 33.16 19.98 91.29 3.38 3.65 3.33 78.62 77.10 
Tachycardia 1640 31.76 25.65 87.28 3.62 3.09 2.94 70.49 76.77 
Congested or 
runny nose 
1638 31.73 10.53 63.96 2.86 1.89 1.83 57.39 53.79 
Joint pain 1598 30.95 20.18 92.04 4.06 3.15 3.04 76.47 62.08 
Blurry vision 1577 30.54 30.01 86.17 2.98 2.69 2.21 79.71 71.85 
Sleeping more 
than normal 
1549 30.00 8.66 89.93 2.63 3.25 3.16 68.82 38.80 
Sore throat 1535 29.73 10.25 55.58 3.28 2.09 2.02 43.06 52.44 
Nausea or 
vomiting 
1481 28.68 16.56 55.70 3.88 2.84 2.77 45.78 70.02 
Chills but no 
fever 
1478 28.63 12.52 58.02 3.30 2.24 2.19 42.69 77.13 






1280 24.79 18.03 96.91 3.80 3.37 3.15 76.17 55.55 
Arrhythmia 1246 24.13 24.37 86.77 3.53 2.84 2.77 79.86 87.72 
Neuropathy in 
hands and feet 
1219 23.61 36.69 89.11 3.71 3.04 2.86 79.66 68.33 
Feeling 
irritable 
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Sadness 1168 22.62 23.12 99.16 3.44 3.04 3.48 79.54 69.26 
Weight loss 1158 22.43 14.91 57.30 1.91 1.55 1.53 36.01 18.05 
Changing 
symptoms 
1157 22.41 16.49 112.04 3.93 3.61 3.61 83.49 82.45 
Phlegm in back 
of throat 
1150 22.27 17.48 90.22 2.86 1.90 1.85 71.83 54.87 
Phantom 
smells 
1137 22.02 39.29 73.49 2.14 1.43 1.54 64.82 81.71 
Constant thirst 1001 19.39 17.05 77.87 2.63 1.74 1.66 67.43 43.96 
Lower back 
pain 
987 19.12 23.56 78.89 4.10 3.17 2.99 65.96 63.32 
Brain pressure 980 18.98 21.56 82.40 4.22 3.56 3.42 73.16 78.27 
Heat 
intolerance 




946 18.32 29.07 76.74 4.25 3.15 2.95 59.83 79.49 
Clogged ears 923 17.88 26.24 76.74 3.12 2.19 2.17 70.21 63.06 
Reflux 921 17.84 32.64 87.83 3.56 2.23 2.23 73.07 72.42 
Burning 
sensations 
901 17.45 30.22 78.29 3.71 2.64 2.58 70.26 81.69 
Calf cramps 898 17.39 34.81 71.81 3.69 2.37 2.28 71.38 84.97 
Hand or wrist 
pain 
898 17.39 40.58 82.63 3.78 3.05 2.47 77.17 67.37 
Weight gain 885 17.14 39.50 95.66 2.72 1.81 2.11 82.94 15.14 
Neck muscle 
pain 
874 16.93 25.46 76.40 4.00 3.07 2.85 66.48 58.81 
Tremors 869 16.83 29.66 76.00 3.35 3.05 2.75 66.28 76.18 
Tinnitus 864 16.73 36.60 93.02 3.01 2.13 2.08 75.35 60.19 
Ear pain or ear 
ache 
863 16.72 26.75 67.91 3.51 2.35 2.23 58.98 69.06 
Rash 821 15.90 39.12 58.84 2.91 1.84 1.87 46.41 46.04 
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base of head or 
occipital nerve 
Dry eyes 806 15.61 26.70 91.38 3.16 2.32 1.99 74.81 54.59 
Low blood 
oxygen 
771 14.93 14.27 70.27 3.61 3.30 3.18 54.22 58.75 
Muscle 
twitching 
769 14.89 38.26 81.27 2.92 2.32 2.21 68.14 79.32 
Postnasal drip 753 14.58 15.95 84.71 2.77 1.80 1.75 67.60 53.25 
Mid-back pain 
at base of ribs 
738 14.29 25.37 77.93 4.05 3.09 2.91 63.01 63.96 
Nerve 
sensations 707 13.69 33.67 96.53 3.72 2.89 2.81 76.38 74.82 
Floaters or 
flashes of light 
in vision 
701 13.58 39.59 83.56 2.67 2.38 2.06 74.04 72.18 
Costochondriti
s 
676 13.09 27.94 83.63 4.11 3.10 2.93 67.01 60.06 
Cold burning 
feeling in lungs 
674 13.05 14.58 79.46 3.93 3.13 3.07 64.39 70.62 
Dry throat 665 12.88 14.70 80.51 3.26 2.24 2.14 68.42 58.80 
Foot pain 655 12.69 40.76 81.84 3.80 2.72 2.62 80.61 68.09 
Upper back 
pain 
641 12.42 23.95 86.36 4.03 3.17 3.02 69.11 62.25 
Cracked or dry 
lips 
633 12.26 20.24 68.34 2.60 1.46 1.46 60.98 36.02 
High blood 
pressure 
627 12.14 30.04 80.68 2.89 2.55 2.41 68.58 55.34 
Dry or peeling 
skin 
614 11.89 32.76 73.58 2.42 1.56 1.55 66.61 29.97 
Mouth sores or 
sore tongue 
586 11.35 39.28 53.78 3.30 1.84 1.85 46.93 47.10 
Feeling of 
burning skin 
579 11.21 31.95 74.25 3.69 2.59 2.49 60.28 72.54 
Swollen hands 
or feet 
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541 10.48 26.36 70.28 3.12 2.07 1.98 52.87 43.81 
Hot blood rush 537 10.40 29.53 85.68 3.34 2.38 2.36 70.02 80.63 
Low 
temperature 










476 9.22 29.31 85.40 2.50 1.79 1.84 66.39 42.44 
Jaw pain 473 9.16 39.07 66.02 3.63 2.30 2.20 58.14 67.23 
Covid toes 452 8.75 35.32 57.07 3.00 1.96 1.85 50.00 44.91 
Spikes in blood 
pressure 
436 8.44 29.12 86.03 3.25 2.98 2.76 63.53 74.77 




420 8.13 33.96 92.54 3.80 2.68 2.70 77.38 65.48 
Painful scalp 383 7.42 40.73 64.69 3.35 2.04 2.02 54.57 57.96 
Menstrual 




381 7.38 33.23 88.32 3.09 2.22 2.24 69.55 44.88 
Kidney pain 379 7.34 33.56 57.00 3.86 2.74 2.60 49.34 67.28 
Eye stye or 
infection 
368 7.13 39.06 39.26 3.28 2.12 1.93 33.70 32.61 
Dry scalp or 
dandruff 
313 6.06 37.44 92.06 2.64 1.56 1.71 79.23 28.75 
Goiter or lump 
in throat 
296 5.73 33.40 84.46 3.57 2.45 2.37 65.54 50.68 
UTI (urinary 
tract infection) 
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263 5.09 31.64 69.13 3.21 2.92 2.77 61.22 59.70 
Kidney issues 
or protein in 
urine 
256 4.96 40.34 66.19 3.28 2.58 2.51 58.59 37.89 




229 4.44 32.90 96.33 3.78 3.69 3.98 68.12 48.91 
Thrush 226 4.38 38.76 50.61 3.00 1.95 2.05 33.63 30.09 
Syncope 213 4.13 33.98 43.92 4.27 3.29 3.15 38.03 62.44 
Hormone 
imbalances 
202 3.91 38.22 99.07 3.42 2.82 2.88 68.32 45.54 
Anemia 169 3.27 37.69 77.19 3.00 3.01 2.90 73.96 23.67 
Elevated 
thyroid 
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Figure 1 Percentage of respondents reporting each COVID-19 symptom
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Figure 2 COVID-19 average symptom onset and duration
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Figure 3 The symptoms of PASC and their impact on survivors’ ability to work
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Supplemental Figure 1 Number of COVID-19 symptoms experienced by PASC survivors 
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